Literature DB >> 11897996

Inhibitory effect of lidocaine on T cells from patients with allergic asthma.

Akihiko Tanaka1, Kenji Minoguchi, Naruhito Oda, Takuya Yokoe, Hirofumi Matsuo, Shinji Okada, Toshiyuki Tasaki, Mitsuru Adachi.   

Abstract

BACKGROUND: Nebulized lidocaine enables dosages of oral corticosteroids to be tapered in the treatment of severe asthma.
OBJECTIVE: We sought to investigate the effect of lidocaine on T cells from patients with allergic asthma.
METHODS: PBMCs and CD4(+) T cells were isolated from 6 patients with asthma and house dust mite allergy. PBMCs were cultured with lidocaine for up to 7 days and then stained with propidium iodide to evaluate the involvement of apoptosis. In addition, the viability of CD4(+) T cells when cultured with lidocaine was investigated. Effects of lidocaine on proliferative response, mRNA expression, and protein production of IL-5 and IFN-gamma by PBMCs were investigated after stimulation with Dermatophagoides farinae, purified protein derivative, and phorbol 12-myristate 13-acetate plus calcium ionophore. The effects of lidocaine on the proliferative response of steroid-insensitive PBMCs from 6 nonallergic donors induced by preculture with IL-2 and IL-4 were also investigated.
RESULTS: No significant increase in the staining of PBMCs with propidium iodide was observed in the presence of 100 micromol/L lidocaine. The viability of CD4(+) T cells was not significantly affected by culture with lidocaine at this concentration. However, lidocaine inhibited, in a dose-dependent manner, the proliferative response and mRNA expression and protein production of IL-5 and IFN-gamma of PBMCs stimulated with D farinae, purified protein derivatives, or phorbol 12-myristate 13-acetate plus calcium ionophore. Preincubation of PBMCs with IL-2 and IL-4 significantly decreased the inhibitory effects of both corticosteroids and lidocaine compared with that after preincubation with medium alone.
CONCLUSION: Lidocaine has immunoregulatory effects on T cells. Therefore, lidocaine might be studied as an anti-inflammatory agent in the treatment of severe steroid-dependent asthma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897996     DOI: 10.1067/mai.2002.122155

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

Review 1.  ["Alternative" effects of local anesthetic agents].

Authors:  S Pecher; B W Böttiger; B Graf; M W Hollmann
Journal:  Anaesthesist       Date:  2004-04       Impact factor: 1.041

2.  Lidocaine down-regulates nuclear factor-kappaB signalling and inhibits cytokine production and T cell proliferation.

Authors:  A Lahat; S Ben-Horin; S B Horin; A Lang; E Fudim; O Picard; Y Chowers
Journal:  Clin Exp Immunol       Date:  2008-03-18       Impact factor: 4.330

3.  Relapse of neuromyelitis optica spectrum disorder associated with intravenous lidocaine.

Authors:  Akiyuki Uzawa; Masahiro Mori; Saeko Masuda; Kazuhiko Aoe; Satoshi Kuwabara
Journal:  Case Rep Med       Date:  2011-05-11

4.  Lidocaine 5% patch for localized neuropathic pain: progress for the patient, a new approach for the physician.

Authors:  Guy Hans; Dominique Robert; Johanna Verhulst; Marcel Vercauteren
Journal:  Clin Pharmacol       Date:  2010-03-30

Review 5.  The 5% Lidocaine-Medicated Plaster: Its Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and Clinical Evidence Supporting its Use.

Authors:  Ralf Baron; Massimo Allegri; Gerardo Correa-Illanes; Guy Hans; Michael Serpell; Gerard Mick; Victor Mayoral
Journal:  Pain Ther       Date:  2016-11-07

6.  Effect of Proparacaine in a Mouse Model of Allergic Rhinitis.

Authors:  Hwan Soo Kim; Sulmui Won; Eu Kyoung Lee; Yoon Hong Chun; Jong-Seo Yoon; Jin Tack Kim; Hyun Hee Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-04-28       Impact factor: 3.372

7.  Nebulized Lidocaine in COVID-19, An Hypothesis.

Authors:  Ziad A Ali; Rif S El-Mallakh
Journal:  Med Hypotheses       Date:  2020-06-01       Impact factor: 1.538

8.  A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis.

Authors:  Marwan N Baliki; Paul Y Geha; Rami Jabakhanji; Norm Harden; Thomas J Schnitzer; A Vania Apkarian
Journal:  Mol Pain       Date:  2008-10-25       Impact factor: 3.395

9.  Lidocaine inhibits staphylococcal enterotoxin-stimulated activation of peripheral blood mononuclear cells from patients with atopic dermatitis.

Authors:  Qingqing Jiao; Honglin Wang; Zhenglin Hu; Yin Zhuang; Weiqin Yang; Ming Li; Xia Yu; Jianying Liang; Yifeng Guo; Hui Zhang; Xilan Chen; Ruhong Cheng; Zhirong Yao
Journal:  Arch Dermatol Res       Date:  2013-04-16       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.